Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study

BACKGROUND: This phase II, open-label, randomised study evaluated whether patients with metastatic pancreatic cancer receiving erlotinib/gemcitabine derived survival benefits from increasing the erlotinib dose. METHODS: After a 4-week run-in period (gemcitabine 1000 mg m(−2) once weekly plus erlotin...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Cutsem, E, Li, C-P, Nowara, E, Aprile, G, Moore, M, Federowicz, I, Van Laethem, J-L, Hsu, C, Tham, C K, Stemmer, S M, Lipp, R, Zeaiter, A, Fittipaldo, A, Csutor, Z, Klughammer, B, Meng, X, Ciuleanu, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260026/
https://www.ncbi.nlm.nih.gov/pubmed/25247318
http://dx.doi.org/10.1038/bjc.2014.494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260026/
https://www.ncbi.nlm.nih.gov/pubmed/25247318
http://dx.doi.org/10.1038/bjc.2014.494

Ejemplares similares